Sign In
Buy MRK
$127.52
+1.25 (+0.99%)
At Close: Jul 22, 2026
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
09:16am, Wednesday, 22'nd Jul 2026
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Merck & Co., Inc. $MRK Shares Sold by Acumen Wealth Advisors LLC
03:40am, Wednesday, 22'nd Jul 2026
Acumen Wealth Advisors LLC lessened its holdings in Merck and Co., Inc. (NYSE: MRK) by 25.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission.
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
01:27pm, Tuesday, 21'st Jul 2026
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first �
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
10:31am, Tuesday, 21'st Jul 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed
Andra AP fonden Has $43.84 Million Stock Holdings in Merck & Co., Inc. $MRK
03:17am, Tuesday, 21'st Jul 2026
Andra AP fonden trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 14.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 364,485 shares of the
Merck (MRK) Declines More Than Market: Some Information for Investors
06:51pm, Monday, 20'th Jul 2026
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio
05:11pm, Monday, 20'th Jul 2026
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
10:44am, Monday, 20'th Jul 2026
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Dimensional Fund Advisors LP Acquires 2,969,856 Shares of Merck & Co., Inc. $MRK
04:45am, Monday, 20'th Jul 2026
Dimensional Fund Advisors LP lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 23.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Co
What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.
02:00am, Monday, 20'th Jul 2026
Many think the next standard cancer treatment will pair two innovations.
Merck & Co., Inc. $MRK Shares Sold by AIA Group Ltd
04:03am, Sunday, 19'th Jul 2026
AIA Group Ltd lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 1.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 375
Allspring Global Investments Holdings LLC Has $81.27 Million Stake in Merck & Co., Inc. $MRK
03:08am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC reduced its position in shares of Merck and Co., Inc. (NYSE: MRK) by 25.5% in the undefined quarter, according to the company in its most recent filing with t
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
03:30pm, Friday, 17'th Jul 2026
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline a
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
01:51pm, Friday, 17'th Jul 2026
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
